Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of participants previously treated with CARVYKTI
2023-505530-10-00Phase 4Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 10
01
Overview
Phase 4, open-label, single-arm trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of subjects with delayed adverse events associated with administration of ciltacabtagene autoleucel, New malignancies and recurrence of preexisting malignancy and 5 more. Planned start Sep 2022; status: authorised.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-505530-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505530-10-00.